Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib rollover study for participants benefiting from prior Incyte parsaclisib trials
2022-501687-18-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of parsaclisib in cancer and Immune disorder (6 arms), sponsored by Incyte. Primary endpoint: Adverse events and serious adverse events. Planned start Oct 2020; status: authorised.
02
Drugs
parsaclisib
03
Conditions
cancerImmune disorder
Beyond the preview
Go deeper on 2022-501687-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501687-18-00.